Skip to content
newprotein.net Explore ingredients
Menu
Cutaway of a pilot hall with fermenter tanks in three sizes linked by pipes to a filtration skid

Supplier profile · Denmark

21st.BIO: fermentation development and scale-up services

21st.BIO develops precision fermentation strains and dairy protein processes in Søborg, Denmark, including beta-lactoglobulin and pilot scale-up.

By the New Protein editorial team · Reviewed

Ingredients from 21st.BIO

IngredientSource groupProteinStrong at
Precision-fermented whey protein Fermentation-derived proteins 85 % Solubility, Gelation, Emulsification, Foaming
Precision-fermented casein Fermentation-derived proteins Gelation, Emulsification, Water binding

What 21st.BIO offers

21st.BIO is a precision fermentation company with its Danish office in Søborg and a US address in Davis, California. It states that it helps companies close the gap between laboratory success and large-scale production. The offer is a technology package of productive microbial strains, optimised fermentation processes and scalable downstream workflows for nature-identical or custom proteins and peptides.

The company says its technology builds on more than 40 years of strain and process engineering from Novo Nordisk and Novonesis, refined further at 21st.BIO. Customers work with it through two models: shared development programmes for nature-identical molecules, and bespoke projects for exclusive protein assets. The split decides who owns the strain and process and who can sell the protein.

The industries page lists dairy proteins, protein sweeteners, collagen, biomaterials, agriculture and biomining. For this database the dairy proteins section is the relevant one, since it covers animal-free versions of whey and milk proteins. Readers who want background on the product class can read the entries on precision-fermented whey and precision-fermented casein.

Dairy protein programmes

The company names three dairy protein targets. Beta-lactoglobulin is described as having strong nutritional value together with foaming, emulsifying and gelling properties, useful for plant-based or hybrid products and dairy alternatives. Alpha-lactalbumin is a whey protein abundant in human milk and scarce in cow’s milk, and caseins make up about 80% of cow’s milk protein.

Its recombinant beta-lactoglobulin, BLG-Essential+, is stated to have self-affirmed GRAS status in the United States, and the company invites partners to join a development programme to enter that market. It states that this protein contains 45% more leucine than commercially available whey protein isolates, is tasteless, remains stable across a wide pH range and tolerates heat, which are supplier claims.

For formulators, a single defined protein behaves differently from whey isolate, which is a mixture. Beta-lactoglobulin alone can give clear acidic drinks and predictable gelation, but it lacks the other whey fractions that contribute to flavour and mouthfeel. Alpha-lactalbumin targets infant formula, clinical nutrition and supplements. Buyers should ask which programmes are open and when supply begins.

Technology and process development

The service chain runs from strain development and lab-scale fermentation through recovery and purification to industrial upscaling. The company lists optimisation of strains for high titer and product stability, and downstream processes built for purity and yield. Titer, meaning grams of protein per litre of broth, and recovery yield drive cost, so request both in any proposal.

Precision fermentation hosts are typically fungi or yeasts engineered to secrete a target protein. A partner should ask which organism is used, how the protein is separated from host proteins, and what residual host DNA and protein limits are met. These matter for allergen labelling and regulatory dossiers, and they should be confirmed in writing before any trial.

Regulatory status is also a project variable. Self-affirmed GRAS is a United States route, and other markets require their own authorisation, for example under the European novel food rules. A buyer planning a product in several regions should ask for the dossier status in each region and what exclusivity arrangements apply before committing a launch date to retailers.

Pilot plant and scale-up

The pilot plant is described as a downscaled full industrial production setup, a mini factory meant to prepare clients for large scale. Total capacity is 3,060 litres in stainless steel fermenters: two of 1,200 litres, two of 300 litres and two of 30 litres. Fermentation and downstream experts guide each project.

Listed services include fermentation process optimisation, scale-up guidance from lab to pilot and commercial scale, process monitoring and troubleshooting, and downstream optimisation to maximise recovery and purity. The company also offers on-demand rental of downstream equipment, technology transfer, selection of a suitable contract manufacturer, documentation and reporting, and training of client teams. Clients keep the data generated in their runs.

Pricing is quoted per project after a compatibility form is completed, and the pilot page presents a standard and a complex project as case studies. A developer should ask about booking lead times, minimum batch commitments and whether an introduction to a contract manufacturer is part of the service, and how long a slot is held.

How a buyer would evaluate the company

Decide first which relationship is needed. A food brand wanting a ready ingredient should ask whether a protein is available in sample or commercial quantity, and on what terms. A protein developer wanting a process should ask about strain ownership, intellectual property, titer targets and who carries the risk if a process fails to scale.

Request analytical data for any protein sample: purity, residual host material, endotoxin where relevant, microbiological limits, solubility, heat stability and flavour in a neutral and an acidic drink. Compare against a whey isolate or a competing recombinant protein under the same conditions. Claims such as 45% more leucine describe composition, while function in the finished food is decided in trials.

Finally, confirm regulatory and labelling positions. Ask which allergen statements apply, since a milk-identical protein is generally treated as a milk allergen in many jurisdictions, and what claims are acceptable. Contact is by email or telephone at the Danish and US offices, and the company suggests booking a meeting through its website to discuss a project.

Frequently asked questions

What does 21st.BIO provide?

The company provides a technology package for precision fermentation of proteins and peptides: microbial production strains, optimised fermentation processes and scalable downstream workflows, offered through shared development programmes and bespoke projects.

Which dairy proteins does it work on?

Its dairy page lists beta-lactoglobulin, alpha-lactalbumin and caseins. The recombinant beta-lactoglobulin is marketed as BLG-Essential+ and the company states it holds self-affirmed GRAS status.

What is the pilot plant capacity?

The company states a total pilot capacity of 3,060 litres, made up of two 1,200 litre, two 300 litre and two 30 litre stainless steel fermenters, plus downstream processing support.

Where is the company located?

The pages list an office at Sydmarken in Søborg, Denmark, and a US address in Davis, California. The company says its technology builds on more than 40 years of strain and process engineering from Novo Nordisk and Novonesis.